Strategic Summary · 2025–2028

Strategic Plan

Where Pain Relief International is going, and how we'll know we're getting there.

This is our public strategic summary for 2025–2028: five priorities that carry the organization from proven technology to population-scale deployment — with the governance, measurement, and review cadence to keep us honest along the way.

Strategic Intent

Expand access to durable, non-pharmacologic pain management for underserved communities — by pairing a reusable, drug-free technology with partnerships and deployment frameworks that scale. The published evidence behind the technology is on Clinical Evidence & Research; the deployment engine is the Global Pain Relief Initiative.

2025Plan adopted; foundations laid — evidence base published, deployment framework defined.
2026Mid-cycle review year: funding diversification and partnership pipeline in focus. (We are here.)
2027Scale phase: regional deployments and manufacturing capacity development.
2028Cycle close: outcomes assessed, next plan drafted from what the data says.

Five Strategic Priorities

Resource Mobilization

Diversify funding across foundations, corporate giving programs, donor-advised funds, and individual sponsorships — so no single source can stall deployment. See For Funders and Ways to Give.

Program Deployment

Expand distribution through community organizations, ministries, and healthcare providers — deployment through structures that already reach the people, at $20 per device delivered at program scale.

Impact Measurement & Learning

Strengthen outcome monitoring so every deployment reports what happened — devices delivered, training completed, usage tracked — and each cycle's data shapes the next.

Technology Stewardship

Refine device durability and usability with the manufacturer, guided by field feedback and the standards set by the published research.

Sustainable Manufacturing & Supply

Develop regional manufacturing capacity so scale brings unit costs down and supply closer to the populations served.

Governance, Risk & Review

Implementation & Governance

The board oversees the plan; leadership executes it. Progress is assessed quarterly and reported annually.

Risk Considerations

We plan around the real risks: funding concentration, partner capacity, supply constraints, and the limits of the current evidence base — named here so they can be managed, not discovered.

Monitoring & Review

A mid-cycle review in 2026 tests the plan against results; quarterly and annual assessments keep priorities honest in between.

Why we publish this: a strategic plan you can read is part of how a young 501(c)(3) (EIN 81-2500234) earns trust. Questions about the plan are welcome — contact us.

The Plan Is Public. So Is the Invitation.

Funders, partners, and institutions: this plan is built to be joined. Pick the priority that matches your capacity, and we'll show you exactly where you fit.